Editorial: Streptozotocin for islet-cell carcinoma.
D058186:Acute Kidney Injury / Q000139:chemically induced; D007516:Adenoma, Islet Cell / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D003919:Diabetes Insipidus / Q000139:chemically induced; D003981:Diazoxide / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007275:Injections, Intravenous; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000503:physiopathology; D013311:Streptozocin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D007328:Insulin; D013311:Streptozocin; D003981:Diazoxide